S

SCYNEXIS
D

SCYX

0.74000
USD
0.02
(2.78%)
مغلق
حجم التداول
8
الربح لكل سهم
-0
العائد الربحي
-
P/E
-1
حجم السوق
28,875,003
أصول ذات صلة
A
ACAD
0.190
(0.82%)
23.250 USD
A
AMRN
-0.070
(-0.45%)
15.450 USD
D
DVAX
0.210
(1.88%)
11.360 USD
NVS
NVS
0.260
(0.22%)
117.680 USD
المزيد
الأخبار المقالات

العنوان: SCYNEXIS

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.